Clinical Trial Update: Phase I/IIa Study Evaluating Safety and Efficacy of an Intratympanic Dose of PIPE-505 in Subjects With Hearing Loss [Phase 1, Phase 2]

View source ↗

Summary

Phase I/IIa study update reporting safety and efficacy data for intratympanic PIPE-505 in subjects with sensorineural hearing loss; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sensorineural Hearing Loss

Drugs mentioned

• PIPE-505

Snippet

Sponsor: Contineum Therapeutics | Conditions: Sensorineural Hearing Loss | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-03-04